Anthera Pharma Offers Outcome Of Interim Futility Analysis In Phase 3 RESULT Trial Of Sollpura: 'study allows for more frequent and higher dose adjustments based upon clinical signs and symptoms than the previous Phase 3 SOLUTION study'